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Background. Pulmonary capillary hemangiomatosis (PCH) is a rare disease, especially in infancy. Four infants have been reported
up to the age of 12 months. So far, no familial patients are observed at this age. Patients. We report three siblings, two female
newborns and a foetus of 15-week gestation of unrelated, healthy parents suﬀering from histologically proven PCH. The ﬁrst
girl presented with increased O2 requirements shortly after birth and patent ductus arteriosus (PDA). She subsequently developed
progressive respiratory failure and pulmonary hypertension and died at the age of ﬁve months. The second girl presented with
clinical signs of bronchial obstruction at the age of three months. The work-up showed a PDA—which was surgically closed—
pulmonary hypertension, and bronchial wall instability with stenosis of the left main bronchus. Transient oxygen therapy was
required with viral infections. The girl is now six years old and clinically stable without additional O2 requirements. Failure to
thriveduringinfancyandasomewhatdelayeddevelopmentmaybetheconsequenceofthediseaseitselfbutalsocouldbeattributed
to repeated episodes of respiratory failure and a long-term systemic steroid therapy. The third pregnancy ended as spontaneous
abortion. The foetus showed histological signs of PCH. Conclusion. Despite the diﬀerences in clinical course, the trias of PCH,
PDA, and pulmonary hypertension in the two life born girls suggests a genetic background.
1.Introduction
Pulmonary capillary hemangiomatosis (PCH) is a rare pul-
monary disease characterized by numerous capillary-sized
blood vessels that proliferate diﬀusely throughout the pul-
monary interstitial tissue, pulmonary blood vessels, and air-
ways [1]. The Venice Clinical Classiﬁcation of Pulmonary
Hypertension displays both PCH and pulmonary veno-
occlusive disease as pulmonary hypertension associated with
signiﬁcantvenousorcapillaryinvolvement[2].Sincetheﬁrst
description by Wagenvoort et al. in 1978 [3], PCH was diag-
nosed in individuals of diﬀerent ages ranging from neonates
to the elderly [4]. In a series of 37 patients with PCH only
f o u rw e r ei d e n t i ﬁ e du pt oa na g eo f7y e a r s[ 5]. Congenital
PCH has been reported in two additional patients [6]. One
was a male twin, stillborn after 30 weeks of gestation. Autop-
sy revealed absent kidneys in addition to PCH. The diamni-
otic, monochorionic twin was alive and well. Another male
newborn presented with severe mitral regurgitation and pul-
monary hypertension requiring cardiac surgery and died at
the age of 9 weeks. PCH was diagnosed post mortem. To our
knowledge only one familial occurrence in three siblings has
been reported, who all died because of PCH and pulmonary
hypertension in young adulthood [7]. None of them had
additional anomalies or malformations. We report for the
ﬁrst time three siblings, two female term newborns and a
foetus stillborn at 15 weeks of gestation, with histologically
proven PCH. Both newborns had patent ductus arteriosus
(PDA) and pulmonary hypertension (PH) which manifested
in the neonatal period and in early infancy, respectively.
2. Patients
2.1. Patient 1. The girl was born after an uneventful preg-
nancy at 42 weeks of gestation as ﬁrst child of unrelated,
healthy parents. The 28-year-old mother reported no prior2 Case Reports in Pulmonology
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Figure 1:Computedtomography(CT)ofthethorax.(a)CTofthethoraxofpatient1attheageof3.5months.Smallcystic,emphysematous
transformations ubiquitously involving both lungs and consolidations in the dorsal parts of the lungs were found. (b) CT of the thorax of
patient 2 at the age of 4 months. Consolidations in both lungs with some cystic areas, a relatively small left lung, and enlarged central
pulmonary arteries with rareﬁcation of the branches in the periphery are shown. Please note the more focal involvement of the lungs
compared to patient 1.
pregnancies, the birth weight was 2860g (7th centile), Apgar
scores after 5 and 10 minutes were 6 and 8, respectively, and
the umbilical artery pH was 7.18. The newborn presented
directly after birth with an increased O2-requirement (frac-
tion of inspired oxygen (FiO2)o f0 . 4 )a n dn e e df o rc o n -
tinuous positive airway pressure (CPAP). Chest radiograph
showed an enlarged heart silhouette with signs of increased
pulmonary blood ﬂow. A hemodynamic signiﬁcant PDA was
closed surgically at the age of 18 days after an unsuccessful
attempt with indomethacin. However, increased oxygen re-
quirement persisted. Echocardiography suggested that PH
and cardiac catheterization showed systemic blood pressure
in the pulmonary arteries at rest and suprasystemic levels
during activity. Pulmonary vein obstruction was excluded.
At the age of 10 weeks, the girl acquired viral pneumonia and
mechanical ventilation became necessary. Chest radiography
showed a seriously enlarged heart-silhouette with cystic and
consolidated areas of the lung. Computed tomography (CT)
of the thorax demonstrated small cystic, emphysematous
transformations of both lungs (Figure 1(a)). Histological
examination of an open lung biopsy performed at the age
of 14 weeks showed ectatic alveoli (Figures 2(a) and 2(b)).
These ﬁndings were interpreted as cystic adenomatoid mal-
formation Stocker type III, and the case was subsequently
published because of the unusual combination of this pul-
monary condition with pulmonary hypertension [8]. Only
the reevaluation of tissue samples together with the lung bi-
opsyofhersister(patient2,see)couldestablishthediagnosis
of PCH in this patient.
Globalrespiratoryinsuﬃciencydevelopedaftertheageof
3 to 4 months. Radiologically, the areas of the lung aﬀected
by abnormal tissue increased. Despite the use of diﬀerent
ventilatory strategies, nitric oxide and iloprost inhalation,
the patient died from cardiorespiratory failure due to a viral
pneumonia at the age of 5 months.
2.2. Patient 2. This girl was born after 38 weeks of gestation.
Pregnancy and delivery were unremarkable, the birth weight
was normal (3440g; 60th centile), and Apgar scores were
10 after 5 and 10 minutes, respectively. On physical exam-
ination, mild anomalies were present such as an umbilical
hernia, a diastasis of the Musculus rectus abdominis,a n da
high arched palate. However, the girl was otherwise asymp-
tomatic until she developed the clinical picture of an ob-
structive bronchitis at the age of 3 months. While the initial
chest X-ray after birth was normal, chest radiography and
CT of the thorax at the age of 4 months showed consol-
idations in both lungs with some cystic areas, a relatively
small left lung, and enlarged central pulmonary arteries
with rareﬁcation of the branches in the periphery (Figure
1(b)). Bronchoscopy demonstrated subtotal stenosis of the
left main malacic bronchus and bronchomalacia in other
bronchi. However, a hemangioma in the left main bronchus
could not be excluded. Repeated echocardiography showed a
PDA without hemodynamic signiﬁcance, a remarkably long
intramural course of the right coronary artery, and—during
follow-up—increasing enlargement of the right ventricle
with thickening of the right ventricular wall. Pulmonary
pressure could only sporadically be estimated by echocar-
diography, but was increased at the age of 4 months and
thereafter to nearly half of systemic arterial pressure. PDA
was surgically closed at the age of 7 months. Open lung bi-
opsies were taken twice, one from the right upper lobe dur-
ing the PDA-operation and another from the left lung at the
age of 12 months. While the ﬁrst biopsy showed only minor
changes suggestive of PCH, the second biopsy conﬁrmed this
diagnosis (Figures 2(c) and 2(d)).
The clinical course of patient 2 was remarkably differ-
ent compared to that of her deceased sister (Table 1). Pa-
tient 2 presented mainly with wheezing and episodes of res-
piratory distress leading to hospital treatment ﬁrst time afterCase Reports in Pulmonology 3
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Figure 2: Lung biopsies of patient 1 (a and b), patient 2 (c and d), patient 3 (e), and control (f). (a) Altered lung architecture with slight
emphysema and slight to moderate thickening of alveolar walls due to proliferation of capillaries. Note venous sclerosis (→) and the capillary
duplications in some alveolar walls. Changes reﬂect pulmonary arterial hypertension (Hematoxylin and Eosin, ×100), (b) High-power view
ofthickenedalveolarseptaduetoproliferationandtortuosityofcapillaries.Endothelialcellsliningtheinnersurfaceofcapillariesaremarked
by CD-34 staining (Immunopoeroxidase, ×200), (c) Irregular emphysematous changes and focal capillary proliferation in thickend alveolar
walls. Changes are less prominent than in patient 1 (Hematoxylin and Eosin, ×100), (d) Capillary proliferation and protrusion of tufts of
capillariesisfoundinsomealveolarsepta(=⇒)andinthewallofavein(→).Endothelialcellsliningtheinnersurfaceofcapillariesaremarked
by CD-31 staining (Imminoperoxidase, ×200), (e and f) Post mortem lung histology of patient 3 (e) versus control (f). pseudoglandular
stage of lung development at 15 weeks of gestational age. Endothelial cells express CD-31. (Immunoperoxidase, ×200), (e) Broadened space
between pseudoglands with proliferation of capillaries in lung tissue of patient 3. Regressive changes are due to advanced autolysis following
intrauterine death, (f) Normal lung architecture at 15 weeks of gestational age.4 Case Reports in Pulmonology
Table 1: Clinical characteristics of the 3 patients with PCH.
Patient 1 Patient 2 Patient 3
Gestational age (wks.) 42 38 15
Malformations —
Umbilical hernia
diastasis m. recti
gothic palate
—
Onset of symptoms 1st day of life 3 months —
Pulmonary symptoms Supplemental oxygen need since birth Recurrent obstructive bronchitis in infancy —
Patent ductus arteriosus Surgical closure in neonatal period Surgical closure at the age of 7 months Prenatal status
Mechanical ventilation Ventilated for almost entire life span Only used for elective surgery —
Pulmonary
hypertension Conﬁrmed during heart catheterization Suspected by echocardiography and
electrocardiography —
Outcome Death at the age of 5 months due to
respiratory failure
Poor growth during ﬁrst years
recurrent
obstructive bronchitis
neuro-developmental delay
Abortion
(a) (b)
Figure 3: Chest X-ray of patient 2 in anterior-posterior condition, (a) Chest X-ray at the age of 3 years: there are signs of hyperlucent and
hyperinﬂation with cystic-imaging areas (→) and laterally ascending ribs as a sign of lung inﬂation. In some areas of the lungs, there are
consolidations. The heart silhouette is enlarged and clips are present in typical location after surgical closure of a patent ductus arteriosus,
(b) Chest X-ray at the age of 5.5 years: persistent signs of bronchial obstruction. Chronic consolidations are found perihilar at the right side
and behind the heart.
3 months of age. Episodes of increased oxygen requirements
occurred only during viral respiratory infections. Symptoms
responded relatively well to inhalations with salbutamol
and ipratropium-bromide. However, systemic steroids were
necessary over prolonged periods of time with good eﬀects.
Except for elective surgery, the girl was never on mechanical
ventilation. Figure 3(a) shows the chest X-ray at the age
of three years. A recent X-ray of the thorax is shown in
Figure 3(b) demonstrating focal chronic consolidations and
bronchial obstruction. Growth and weight gain of patient 2
were blunted during the ﬁrst years of life, but height and
weight are now, at the age of seven years, at the 12th and
56th centile, respectively. There is a persisting retardation
in motor and speech development. However, the girl con-
tinuously improves her skills and was able to visit a regular
kindergarten. At the moment she visits a specialized school
for physically handicapped children because of reduced
cardiopulmonary capacity limiting even everyday activities.
The girl does not need supplemental oxygen due common
colds since her sixth year of life.
2.3. Patient 3. After an initially unremarkable pregnancy,
intrauterine death was diagnosed at 15 weeks of gestation
and spontaneous abortion occurred. Histological examina-
tion of the fetal lung showed abnormal capillaries (Figures
2(e) and 2(f)). No other abnormalities were diagnosed. The
cause for the stillbirth remained unclear.
3. Discussion
To our knowledge, we report the ﬁrst cases of familial,
congenital PCH with clinical manifestation in the neonatalCase Reports in Pulmonology 5
period or early infancy, respectively. While the pulmonary
disease was evident already at birth in patient 1, patient 2
became symptomatic only after three months. PCH was
established in both patients by histological and immunohis-
tologicalexaminationoflungtissue.Changesassociatedwith
PCHwerenotdiﬀerentfromthosereportedinotherpatients
with PCH [1, 3].
As in patient 1 and also in patient 2, PCH is often
associated with PH [9]. Leading clinical symptoms like
pulmonary distress and pulmonary hypertension in PCH
havetobediﬀerentiatedfromotherdiseaseslikehematologic
or immunologic diseases [10]. Interestingly, some molecular
ﬁndings suggest that pulmonary veno-occlusive disease
(PVOD) and PCH might represent diﬀerent phenotypes of
the same disease [2]. It has been suggested that capillary
growth in and around the pulmonary vessels is involved in
thepathogenesisofPHinPCH[11].Itis,however,unknown
whether a dysregulation in molecular mechanisms of pul-
monary vascular development is responsible for PCH [12].
Mostlikely,itdevelopssecondarytoareactiveveno-occlusive
phenomeneon in combination with recurrent pulmonary
hemorrhage, thrombosis, and infarction [13, 14]. Mechan-
ical intravascular hemolysis was reported in one patient
with PCH [5]. Increased platelet-derived growth-factor and
growth-factor receptor gene expression may play a role in
the pathogenesis of PCH [15]. One might speculate that
acquired disorders of the pulmonary capillary and venous
structure more often present as PVOD. However, the genetic
backgroundofPCHisstillnotunderstood.Apossibleimpact
of genetic factors is further supported by the familial PCH
reported formerly [7] and in our patients. Recently, genetic
deletions of the FOX gene cluster were found in alveolar
capillary dysplasia with misalignment of pulmonary veins,
another disorder of pulmonary blood vessels [16].
While there might be some similarities to vascular neo-
plasms in adults, the few children with PCH reported under
the age of 6 months presented with severe malformations of
the cardiovascular or renal system [6]. Based on the familial
occurrence in our patients, we speculate that PCH in at least
some patients with the congenital or infantile form of the
disease could have a genetic background.
Despite histological similarities in patients 1 and 2, the
clinical course was remarkably diﬀerent, possibly reﬂecting
a nearly complete involvement of the lungs in patient 1 but
only focal distribution of hemangiomatosis in patient 2. The
diagnosis of PCH in neither patient could be made by chest
X-ray. More sensitive but not speciﬁc was the imaging of the
lungs by CT of the thorax in agreement with previous studies
[17, 18]. Though lymph node pathology has been described
in PCH, lymphatic congestion or lymph node hyperplasia
was not evident in our cases [19]. Diﬀerential diagnosis to
be considered in case of pulmonary hypertension and the
observed CT changes may include idiopathic pulmonary
arterial hypertension, PVOD, pulmonary interstitial ﬁbrosis,
micro-thrombo-embolic pulmonary vascular disease, pul-
monary lymphangiomatosis [20], and cystic adenomatoid
lung malformation. Histological examination was required
to establish the diagnosis of PCH in our patients. Though
emphysematous changes in PCH of adults are missing, these
emphysematous changes seem to be typical for familial cases.
An increased risk of severe bleeding during biopsy was
reported recently [21], but noninvasive diagnostic in our
cases was not conclusive. As mentioned earlier, the clear
diﬀerentiation of PCH from cystic adenomatoid lung mal-
formation was diﬃcult in patient 1 [8] because there was
absence of bronchial cartilage with multiple small cysts in all
segments of the lung. In retrospect staining for vasculature
could clearly identify the changes typical for PCH with mas-
sive increase in capillaries inﬁltrating alveolar septa and the
walls of vessels.
The age of manifestation and the clinical signs diﬀer
largely between the patients reported in the literature [1, 3,
6, 7, 15]. In our patients presentation occurred in fetal and
neonatal time and infancy, respectively. A further 30-weeks-
old stillborn preterm infant withPCH associated with absent
kidneys has been reported [6]. In addition, a term newborn
of 38 weeks’ gestation with PCH associated with severe
mitral regurgitation and endocardial ﬁbrosis died at the age
of 9 weeks [6]. Some patients with PCH manifestation in
childhood have been described [5, 22]. However, most pa-
tients with PCH are diagnosed at the age of 20–40 years
[22]. Clinical features also diﬀer among patients. Although
two thirds of all patients primarily suﬀer from signs of dys-
pnea [5], hemoptysis is described as ﬁrst clinical symptom
as well [23, 24]. X-ray ﬁndings are not speciﬁc and CT-
scans of the thorax usually show nonspeciﬁc alterations [5].
Therefore, PCH is frequently misdiagnosed ante mortem
when biopsy is not performed. Diagnosis of PCH might be
substantiated by bronchoalveolar lavage and—in older chil-
dren and adults—by assessing CO diﬀusing capacity [5, 21].
Right ventricular hypertrophy can be detected by electrocar-
diography, because progressing disease results in pulmonary
hypertension with poor prognosis. PCH is frequently misdi-
agnosed ante mortem. Though it is known that open lung
biopsy can result in massive hemorrhage in some cases, this
invasive procedure has to be considered in patients with
pulmonaryhypertensionofunknownaetiologytoeventually
prove a speciﬁc diagnosis. In our two patients, biopsy was
p e r f o r m e dw i t h o u ta d v e r s es i d ee ﬀects.
Due to the very low incidence of PCH, no therapeutic
regimens have been deﬁned so far. Therapeutic strategies like
iv-epoprostenoltolowerPHmayproducepulmonaryedema
in patients with PCH and are therefore contraindicated [5,
21]. Because of the malgenesis of pulmonary vessels, steroids
and cyclophosphamide were used, but also given unsuccess-
fully in some patients [22]. In contrast our patient 2 seemed
tobeneﬁtfromsystemicsteroidsatleastclinicallyintheshort
run. α-Interferon was reported to be eﬀective in one patient
[5, 25, 26]. Experimental use of the antibiotic drug doxycy-
clineasaninhibitorofangiogenesiswassuccessfulinanother
patient [23]. In adults, lung-transplantation can be oﬀered
[2, 21]. With the exception of systemic steroids, we did not
use any of the above mentioned therapeutic strategies.
4. Conclusion
Our patients show that familial PCH might occur early
in life. The rare disorder was not associated with other6 Case Reports in Pulmonology
life-threatening pathology but with signs of pulmonary hy-
pertension and a persistent patent ductus arteriosus. Thus,
the diagnosis should be considered in young children with
right heart failure, right ventricular hypertrophy, or pul-
monary hypertension. Open lung biopsy was required to
conﬁrm the diagnosis. There is no established therapy for
PCH early in infancy, but our patients demonstrate that
outcome may be quite variable, even within a family. Despite
the diﬀerences in clinical course, the trias of PCH, PDA, and
pulmonary hypertension in the two life born girls suggests a
genetic background.
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